Minutes from the Extraordinary General Meeting 6 June 2016
(Oslo, Norway, 6 June 2016) The Extraordinary General Meeting of Bionor Pharma ASA (OSE:BIONOR) today adopted all items and resolutions as proposed in the notice.
At the Extraordinary General Meeting, Helene Jebsen Anker was elected as new Board member.
The minutes of the Extraordinary General Meeting is attached hereto.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Unni Hjelmaas, Acting CEO, +47 915 19 651, firstname.lastname@example.org
Jørgen Fischer Ravn, VP Investor Relations & Communications, +45 2030 3903, email@example.com
Bionor Pharma is a Norwegian biopharmaceutical company focused on advancing its proprietary therapeutic vaccine Vacc-4x in combination with other medicines toward a functional HIV cure. The company believes it has first mover potential based on clinical results to date and early adoption of now recognized clinical strategy. In December 2015, Bionor announced that the HIV ’Shock & Kill’ trial REDUC with Vacc-4x and romidepsin successfully met its primary endpoint by reducing latent HIV reservoir and further demonstrated control of viral load. Bionor is currently planning BIOSKILL, a proof-of-concept Phase II trial, which may lead to a major value inflection point and partnering opportunities. Bionor currently retains full ownership rights to Vacc-4x, i.e., the upside potential from partnering or licensing remains with the company. Bionor is based in Oslo, Norway and is listed on Oslo Børs (OSE:BIONOR). More information about Bionor is available at www.bionorpharma.com.